Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma
Top Cited Papers
Open Access
- 1 December 2005
- journal article
- Published by American Society of Hematology in Blood
- Vol. 106 (12) , 3777-3784
- https://doi.org/10.1182/blood-2005-03-1173
Abstract
Bortezomib, a proteasome inhibitor with efficacy in multiple myeloma, is associated with thrombocytopenia, the cause and kinetics of which are different from thKeywords
This publication has 23 references indexed in Scilit:
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- A phase 2 study of two doses of bortezomib in relapsed or refractory myelomaBritish Journal of Haematology, 2004
- Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic MalignanciesJournal of Clinical Oncology, 2002
- NF-κB as a Therapeutic Target in Multiple MyelomaJournal of Biological Chemistry, 2002
- Serum Levels of Endogenous Thrombopoietin and Granulocyte-Colony Stimulating Factor in Patients with Acute or Lymphoma Type Adult T-cell Leukemia During Multicycle ChemotherapyLeukemia & Lymphoma, 2002
- The physiological response of thrombopoietin (c‐Mpl ligand) to thrombocytopenia in the ratBritish Journal of Haematology, 1999
- ThrombopoietinNew England Journal of Medicine, 1998
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998
- Plasma thrombopoietin levels in thrombocytopenic states: implication for a regulatory role of bone marrow megakaryocytesBritish Journal of Haematology, 1998
- A gentle fixation and permeabilization method for combined cell surface and intracellular staining with improved precision in DNA quantificationCytometry, 1991